BioVaxys and Adiverna Partner to Develop World's First AI-Designed mRNA Vaccines for Companion Animals
核心洞察
BioVaxys Technology Corp (搜索). and Adiverna LLC (搜索) have entered into a research agreement to develop mRNA-based vaccines for rabies (搜索), leptospirosis (搜索), and feline infectious peritonitis (搜索) in dogs and cats.
The collaboration combines BioVaxys' DPX immune educating platform with Adiverna's AI-designed mRNA sequences, potentially creating the world's first mRNA veterinary vaccines.
No mRNA vaccines (搜索) are currently approved for companion animals, representing a significant market opportunity in the global veterinary vaccine sector valued at billions of dollars.
BioVaxys Technology Corp (搜索). and Adiverna LLC (搜索) announced a research collaboration to develop mRNA-based vaccines for companion animals, targeting rabies (搜索), leptospirosis (搜索), and feline infectious peritonitis (搜索) (FIV (搜索)) in dogs and cats. The partnership combines BioVaxys' DPX immune educating platform with Adiverna's artificial intelligence-designed mRNA sequences, potentially creating the world's first mRNA vaccines (搜索) for veterinary use.
Groundbreaking AI-Driven Approach
Adiverna is pioneering veterinary healthcare by leveraging proprietary artificial intelligence technology to design and optimize mRNA sequences specifically for companion animals. Currently, no mRNA vaccines (搜索) are approved for these animals, making this collaboration groundbreaking. The company's AI platform utilizes machine learning algorithms and advanced bioinformatics to analyze extensive datasets, identifying and predicting the most effective mRNA sequences that code for protective broadly cross-neutralizing antigens against diseases such as FIV (搜索), rabies (搜索), and leptospirosis (搜索).
The AI-designed mRNA platform offers significant dose-sparing potential, reducing the amount of vaccine required while still eliciting robust immune responses. This approach aims to overcome limitations of traditional vaccines by offering faster development times and improved efficacy.
DPX Platform Innovation
The BioVaxys DPX platform represents a major innovation in vaccine development, offering solutions to limitations faced by vaccines using other antigen delivery methods, such as lipid nanoparticles. The platform presents antigens to the immune system using a novel non-systemic mechanism of action that does not release active ingredients at the injection site, but rather forces active uptake of immune cells and delivery into lymphatic nodes.
Kenneth Kovan, President and Chief Operating Officer of BioVaxys, explained the advantages: "Challenges faced by LNP-based vaccine formulations are it can spill out of the injection site leading to systemic inflammatory responses, with their systemic delivery leading to degradation by nucleases and removal by macrophage phagocytosis. Due to their relatively short half-life, LNPs can also show instability under in vivo conditions, and with degradation affecting their storage, delivery, and overall efficiency."
Superior Vaccine Performance
The "no release" mechanism allows for active uptake of antigens such as mRNA and other polynucleotides, peptides, proteins, and virus-like particles into immune cells and lymph nodes for sustained activation of the immune system. T cell flow is sustained over a longer duration than traditional vaccines.
Traditional vaccines for companion animals are generally effective for either one year or three years, depending on the specific product and regulations. While current rabies (搜索) vaccines usually last one year, subsequent boosters can be labeled for three years of protection. DPX-formulated mRNA vaccines (搜索) would offer significant advantages over traditional vaccines by delivering superior, longer-lasting immunity with fewer doses, together with high-level, rapid, and durable neutralizing antibody responses.
Kovan added that "Data from proof-of-concept studies of DPX-mRNA formulations demonstrate that DPX provides enhanced in vitro and in vivo stability of packaged mRNA, attracts a therapeutically unique subset of Antigen Presenting Cells (APCs) to the injection site for targeted uptake of mRNA by the immune system, and that immunization with DPX containing mRNA induces specific immune responses towards encoded antigens."
Substantial Market Opportunity
The global rabies (搜索) veterinary vaccines market for inactivated and modified-live virus vector products is valued at US$785 million in 2024 and is projected to reach approximately US$1.1 billion by 2030, growing at a 5.8% CAGR. Annual sales for canine leptospirosis (搜索) killed vaccine formulations are part of the broader dog vaccine market, which was valued at approximately $2.10 billion in 2025. However, short durability, serotype specificity and adverse reactions make these vaccines difficult to apply.
The FIV (搜索) vaccine market is part of the broader feline vaccines sector, which is projected to reach USD 3.28 billion by 2034, growing from USD 1.77 billion in 2025. Driven by mandatory pet vaccinations, increasing disease awareness, and rising pet ownership, the market is dominated by companion animal vaccination in North America, with the Asia/Pacific region experiencing rapid growth due to increasing vaccination campaigns in countries like India and China.
Manufacturing and Safety Advantages
A DPX mRNA vaccine would not use viral material and would have fewer impurities, reducing risks associated with injecting foreign, inactivated viruses. The platform incorporates advantages including non-systemic depot delivery, micro-dosing, excellent shelf-life stability, and clinically demonstrated efficacy, safety and tolerability in both human and animal health use.
"We are very excited to be working with Adiverna to develop what could be the world's first mRNA veterinary vaccine. We believe the clinically proven advantages of the DPX platform formulated with Adiverna's AI-designed mRNA sequences will provide for a superior product," adds Kovan. "With demonstrated in vivo proof of concept of DPX mRNA formulations, this 'proof of product' will further our partnering discussions utilizing DPX mRNA formulations in human therapeutic applications."
Company Backgrounds
BioVaxys Technology Corp (搜索). is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and HapTenix tumor cell construct platform. The company's clinical stage pipeline includes maveropepimut-S (MVP-S) in phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (搜索) (DLBCL) and platinum resistant Ovarian Cancer (搜索).
Adiverna is an innovative biopharmaceutical company registered in Ladera Ranch, CA, dedicated to advancing veterinary medicine through development of cutting-edge mRNA-based vaccines and therapies. The company focuses on enhancing the health and well-being of companion animals by utilizing its proprietary mRNA technology platform for precise and effective immunizations against various infectious diseases.